CONTINUE TO SITE

OR WAIT null SECS

Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions Expert on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL Management of Transplant-Ineligible Multiple Myeloma Register: Improving Outcomes in Newly-Diagnosed Multiple Myeloma Including High-Risk Disease Taking a Patient-First Approach to Treatment in CLL Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 FusionsExpert on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCLManagement of Transplant-Ineligible Multiple MyelomaRegister: Improving Outcomes in Newly-Diagnosed Multiple Myeloma Including High-Risk DiseaseTaking a Patient-First Approach to Treatment in CLLUpdates in Therapies of Relapsed and Refractory Follicular Lymphoma

Clinical

View More Brain Cancer Breast Cancer Colorectal Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Hematology Leukemia Lung Cancer Lymphoma Pediatric Cancers Skin Cancer

Brain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer

News

All News NP/PA Practice Management Technology

All NewsNP/PAPractice ManagementTechnology

Media

Around the Practice Between the Lines Clinical Consult Enduring Webinars Expert Interviews Medical World News OncView Podcasts Readout 360 Tumor Board Series

Around the PracticeBetween the LinesClinical ConsultEnduring WebinarsExpert InterviewsMedical World NewsOncViewPodcastsReadout 360Tumor Board Series

Conferences

Publications

About Oncology Journal MBCC Abstract Supplement Oncology Journal

About Oncology JournalMBCC Abstract SupplementOncology Journal

Events

Live Events Virtual Events

Live EventsVirtual Events

CME/CE

Resources

Contemporary Concepts Image IQ Partners Polls Quizzes Slideshows Sponsored Tumor Board

Contemporary ConceptsImage IQPartnersPollsQuizzesSlideshowsSponsoredTumor Board

eNewsletter Print Subscription

eNewsletterPrint Subscription

CureToday.com
OncLive.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Spotlight

Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions
Expert on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL
Management of Transplant-Ineligible Multiple Myeloma
Register: Improving Outcomes in Newly-Diagnosed Multiple Myeloma Including High-Risk Disease
Taking a Patient-First Approach to Treatment in CLL
Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

ClinicalSee All >

Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer

CureToday.com
OncLive.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Andrew Zelenetz, MD, PhD | Authors

Determining the Cell of Origin in DLBCL

September 26, 2018

Dr. Andrew Zelenetz spoke with Cancer Network about the importance of determining the cell of origin in patients with DLBCL.

Selective benefit in high-risk patients, but won’t alter clinical practice

September 01, 2008

The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center.